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Abstract 
Purpose: To investigate the effect of mebendazole on an in vivo solid tumor model of fibrosarcoma in 
hamsters. 
Methods: 24 Syrian golden hamsters of both sexes with the approximate body weight of 100g were 
randomly distributed in 2 experimental and 2 control groups, with 6 animals in each group. BHK-21/C13 
cells (2 x 106) in 1 mL Glasgow Minimum Essential Medium (GMEM) were injected subcutaneously into 
the back of each animal in 3 groups. The experimental groups were treated with mebendazole (460 
mg/kg) via a gastric tube on a daily basis, immediately after tumor inoculation. In addition, one 
experimental group received deoxycholic acid 20 mg/kg once a day. After 2 weeks, when the tumors 
were approximately 1 - 2 cm in the control group, all the animals were sacrificed, and their blood 
collected for laboratory analysis. The tumors were excised, their weight and diameters measured, and 
the volumes calculated. The tumor samples were histopathologically assessed and the main organs 
toxicologically analyzed. Images were taken and processed by an imaging software, and Ki-67-positive 
cells in the tumor samples were quantified.  
Results: Mebendazole diminished tumor mitosis from 18.5 ± 3.02 to 13.5 ± 3.45 (p < 0.05), vasculature 
and tissue penetration, and increased necroses in tumor slices. Tumor volume and weight were 
insignificantly attenuated. Toxicity was not observed.   
Conclusion: Mebendazole might be an effective non-toxic agent in sarcoma therapy.   
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Published results of preclinical investigations 
show that mebendazole, a registered 
antiparasitic drug widely used in endemic tropical 
regions, is effective against cancer cell 
proliferation. Clinical trials of mebendazole’s 
anticancer effect have not yet been completed. 
[1]. Mebendazole exhibits anticancer activity on: 
osteosarcoma and soft tissue sarcoma [2]; 
melanoma [3,4]; meduloblastoma [5,6]; 
glioblastoma multiforme [7]; acute myeloid 
leukaemia [8,9]; lung [10], breast [11], 
hepatocellular [12] colorectal [2,13,14], 
adrenocortical [15,16], and ovarian [17] 
carcinoma. 
 
Although mebendazole has shown a significant 
antiproliferative effect in vitro, its therapeutic 
antitumor value in vivo is still uninvestigated and 
the mechanism of action has not been clarified 
jet. Only a few papers have been published 
about mebendazole’s anticancer effect on solid 
tumors, including sarcomas, in experimental 
animals. Therefore, the aim of this study is to 
investigate if mebendazole (given alone or in 
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combination with deoxycholic acid), can 
suppress fibrosarcoma growth in hamsters. 
 
BHK (Baby Hamster Kidney) cells were used in 
our study. The primary cultures from which the 
Syrian hamster fibroblast cell line BHK-21 was 
produced were prepared in March 1961 from the 
kidneys of 5 one-day-old hamsters from litter No. 
21. Nineteen days after a change in growth rate 
was first observed, 8 clones were grown from 
single cells in a small drop of medium under 
mineral oil. One of these designated BHK-21/13 
(or C13) cells has been extensively examined 
and is the source of the majority of BHK cells 
distributed in laboratories all over the world. 
Rapid growth and high cloning efficiency of BHK-
21/C13 cells combined with low chromosome 
numbers make them especially suitable for 
various preclinical experiments [18]. 
 
The BHK-21 line of Syrian hamster fibroblasts is 
widely used for research on viruses and 
neoplastic cell transformations in vitro [19-22]. 
Some BHK-21 clones (for example C-13) induce 
hamster tumors [22]. As previously described in 
the literature [22,23], BHK cells are capable of 
both reproducing themselves in hamster tissues 
and provoking tumors. 
 
Subcutaneous (s.c.) inoculation of 107 BHK-21 
clone 13 cells produced a fibrosarcoma that 






The study was carried out on 24 adult Syrian 
golden hamsters about 12 weeks old 
(approximate body weight 100 g), male and 
female. The investigation complies with 
“Principles of Laboratory Animal Care” [24]. 
Ethical approval for the animal studies ref. No. 
01-78/18-5 was obtained on 26th April 2016 by 
the Ethics Committee of the University of Novi 
Sad, Faculty of Medicine, Republic of Serbia. 
 
The hamsters were randomised into 2 treated 
and 2 control groups (with 6 animals in each 
group). The BHK-21/C13 cell culture (2 x 106 in 1 
mL Glasgow Minimum Essential Medium - 
GMEM) was inoculated s.c. with an insulin 
syringe, at a 45 degree angle on the right side of 
hamsters’ loin for the production of the BHK 
fibrosarcoma. The treatment in two experimental 
groups was initiated immediately after the s.c. 
inoculation of BHK-21/C13 cells and continued 
for 14 days (until tumor diameters were 
approximately 1 - 2 cm in the untreated control 
group). At the end of the experiment, all animals 
were sacrificed, including the second control 
group without tumor inoculation, which was 
treated with the same dose of mebendazole as 
the experimental groups for 14 days. The 
animals were sacrificed by 10 - 15 minutes 
prolonged anesthesia, with pentobarbital 30 
mg/kg administered intraperitoneally. 
 
Mebendazole, suspended in pure olive oleum, 
was administered once a day via a gastric tube 
at a dose of 460 mg/kg (in 1 mL per 100 g 
weight). One experimental group received 
additional deoxycholic acid as an adjuvant, 20 
mg/kg once a day (in 1 mL of water per 100 g 
weight). The control group with tumors only 
received isovolemic vehicle (1 ml/100 g per 
animal). 
 
The tumors were excided after the sacrifice. 
Tumor weight and size were measured. Tumor 
volume was calculated as L  S2/2 (where L was 
the longest, and S the shortest diameter). Tumor 
slices were analysed histopathologically and 
immunohistochemically (Ki-67) for the verification 
of tumor growth. Blood samples were collected 
for conventional blood tests (erythrocytes, 
leucocytes, lymphocytes, monocytes, 
granulocytes, platelets, hemoglobin, hematocrit, 
MCV, MCH, MCHC, serum proteins, albumins, 
sedimentation, partial thromboplastin time). Body 
weights were measured for hamsters daily to 
evaluate possible side effects. The main organs 





The tumor samples were treated with methanol, 
4 % BSA/PBS and anti-Ki-67 pAb at 25 C. The 
secondary antibody was polyclonal anti-rabbit 
FITC. Hoechst 33256 (Sigma) was used for 
nuclei counterstaining. Leica MC190HD camera 
was used for taking images, which were 
processed by software UTHSCSA Image Tools 
for Windows Version 3.00 [25]. The numbers of 
Ki-67-positive cells were counted on 20 tumor 
images of each animal and the mean values 





Mean ± SD was calculated for experimental data. 
The differences between the treated and control 
groups of animals were determined using 
Student´s t-test (for small independent samples) 
for tumor weight, volume, mean number of Ki-67-
positive cells marked on images and other 
measured parameters. Statistical analysis was 
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performed by Statistica 13.0. Statistically 




The subcutaneous inoculation of BHK-21/C13 
cells into hamsters resulted in fibrosarcoma 
formation at the site of injection in all inoculated 
animals. Treatments with mebendazole and 
mebendazole with deoxycholic acid significantly 
reduced the proliferation status of tumor cells (p 
< 0.05), as shown by Ki-67 staining on hamster 
tumor sections (Table 1). In our experiment, 
tumor volume and weight were not significantly 
changed in either of the treated groups, relative 
to the control group (p > 0.05). 
 
The histopathological evaluation of investigated 
tumors (Figure 1, Figure 2, Figure 3 and Figure 
4) revealed reduction of vasculature, decrease of 
tissue penetration and expansion of necroses 
with mebendazole treatment. 
 
Mebendazole treatment had a significant effect 
on the body weight of the animals during the 
course of the study (Table 1).  
 











X  for 20  
Control group without mebendazole treatment, with inoculated tumor 
1 91 95 F 2060 1.50000 17 
2 105 117 F 6880 5.00000 23 
3 93 94 F 260 0.18750 14 
4 94 110 F 1720 1.00000 20 
5 105 101 M 2910 2.11981 18 
6 97 95 M 1400 1.25025 19 
X  97.5 102  2538 1.84293 18.5 
±SD 6.12 9.51  2297 1.67114 3.02 
Control group without tumor inoculation, treated with 460 mg/kg mebendazole 
1 90 92 F 0 0 0 
2 102 112 M 0 0 0 
3 100 110 M 0 0 0 
4 88 90 F 0 0 0 
5 91 90 M 0 0 0 
6 102 105 F 0 0 0 
X  95.50 99.83     
±SD 6.50 10.32     
Treatment with 460 mg/kg mebendazole 
1 110 90 M 730 0.448 12 
2 116 86 M 980 0.567 13 
3 114 92 M 2110 1.608 14 
4 105 95 F 2570 1.710 16 
5 110 88 F 690 0.395 8 
6 102 100 M 3010 2.280 18 
X  109.5 91.83  1682 1.168 13.5 
±SD 5.25 5.08  1012 0.8001 3.45 
p (t-test) < 0.01  > 0.05 > 0.05 < 0.05 
Treatment with 460 mg/kg mebendazole and 20 mg/kg deoxycholic acid 
1 103 100 F 1250 0.690 13 
2 95 85 M 3120 2.490 18 
3 110 98 M 620 0.377 8 
4 117 105 F 1320 0.710 13 
5 102 90 M 765 0.480 12 
6 98 84 F 2415 1.860 15 
X  104.2 93.7  1582 1.1012 13.17 
±SD 8.08 8.60  983 0.8645 3.31 
p (t-test) > 0.05  > 0.05 > 0.05 < 0.02 
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Figure 1: BHK fibrosarcoma: subcutaneous 




Figure 2: BHK fibrosarcoma: a) subcutaneous 




Figure 3: BHK fibrosarcoma: a) penetration into 
the subcutaneous musculature and the invasion 
of dermal structures; b) mitoses 
 
Experimentally obtained values: the number of 
red and white blood cells and platelet, 
haemoglobin levels, hematocrit, serum proteins, 
sedimentation, activated partial tromboplastin 
time and other blood laboratory values, were 
statistically compared between the treated and 
control groups, but no significant difference was 
observed. 
 
An examination of the main organs revealed no 
pathological or toxicological changes in the 




Mebendazole has been shown to cause tubulin 




Popovic et al 





Figure 4: BHK fibrosarcoma: a) tumour angiogenesis; b) lymphoplasmacytic inflammatory cell 
infiltration and tumour necrosis 
 
Microtubules in the lung cancer culture were 
effective targets for anticancer therapy with 
mebendazole. This therapy blocked mitosis, 
induced apoptosis of lung cancer cells, activated  
caspase and released cytochrome c [10]. Bcl-2 
inactivation is one possible explanation for 
mebendazole’s anticancer effect on melanoma 
cells [3,4]. 
 
In human therapeutic concentrations, 
mebendazole inhibits Hedgehog signaling 
pathway and reduces the growth of human 
medulloblastoma cells [26]. 
 
Like other antimicrotubular drugs, mebendazole 
can block tumor supply with blood by 
depolymerizing microtubules in tumor 
vasculature cells. [27]. This is in accordance with 
our histopathological findings on the investigated 
tumor vasculature. 
 
In this experiment, histopathological 
improvements of the investigated tumors were 
observed, but we suppose that the short duration 
of mebendazole treatment was the main reason 
that the tumor volume and weight remained 
insignificantly changed in both treated groups. 
The combination with deoxycholic acid gave a 
slight advantage with respect to pathohistological 
properties probably due to better penetration of 
mebendazole in tissues. The verification of these 
preliminary results is ongoing with pretreatment 
(treatment before tumor inoculation), higher 
doses (30-50 % LD50), dose dependency 
evaluation and a longer treatment period on 
larger groups of experimental animals. 
 
So far, no clinical trials on the anticancer effects 
of mebendazole have been completed [1]. 
Regarding tumour control with mebendazole 
therapy, only one case report of adrenocortical 
cancer [16] and one case report of colon cancer 
[14] can be found in the literature. 
 
Future clinical trials will elucidate whether 
mebendazole has the potential to become an 





Since non-toxic mebendazole p.o. doses, given 
post-BHK21/C13 cell inoculation, inhibits 
sarcoma cell proliferation in hamsters, 
mebendazole may be a safe novel candidate for 
adjuvant human anti-cancer therapy. However, 
further investigations are required to ascertain its 
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